Ultragenyx Pharmaceutical (RARE) : The money flow analysis of Ultragenyx Pharmaceutical (RARE) indicates a $2.21 million of outflow was on downticks, whereas, the investors on Monday gobbled up stocks worth $4.23 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.91 and so was the total money flow at $2.02 million. The bulls lapped up $1.51 million worth of block trades on upticks. The money flow was $1.51 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Ultragenyx Pharmaceutical (RARE), pushing it down by -0.39% for the day. The stock slid $0.21 and traded at $52.96 during the day. Nonetheless, the stock is -0.73% over the previous weeks close.
Ultragenyx Pharmaceutical Inc. has dropped 27.37% during the last 3-month period . Year-to-Date the stock performance stands at -52.28%. Shares of Ultragenyx Pharmaceutical Inc. appreciated by 1.23% during the last five trading days but lost 10.43% on a 4-week basis. In a related news,The (Chief Medical Officer) of Ultragenyx Pharmaceutical Inc., Agarwal Sunil sold 650 shares at $54.16 on June 20, 2016. The Insider selling transaction had a total value worth of $35,204. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Ultragenyx Pharmaceutical (NASDAQ:RARE): stock turned positive on Monday. Though the stock opened at $53.46, the bulls momentum made the stock top out at $54.39 level for the day. The stock recorded a low of $51.8738 and closed the trading day at $53.53, in the green by 0.68%. The total traded volume for the day was 700,260. The stock had closed at $53.17 in the previous days trading.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).